[89Zr]Zr-Girentuximab PET/CT for the targeted diagnosis of clear cell renal cell carcinoma (ccRCC)
Loading...
Supplementary material
Other Title
Authors
Painting, A.
Vyas, Madhusudan
Fagan, J.
Lim, R.
Vyas, Madhusudan
Fagan, J.
Lim, R.
Author ORCID Profiles (clickable)
Degree
Grantor
Date
2023-09-09
Supervisors
Type
Conference Contribution - Oral Presentation
Ngā Upoko Tukutuku (Māori subject headings)
Keyword
cancer patients
renal cancer
radionuclide therapy
diagnosis
renal cancer
radionuclide therapy
diagnosis
ANZSRC Field of Research Code (2020)
Citation
Painting, A., Vyas, M., Fagan, J., Lim, R. (2023, September, 9 -10). [89Zr]Zr-Girentuximab PET/CT for the targeted diagnosis of clear cell renal cell carcinoma (ccRCC) [Paper presentation]. ANZSNM-NZ Symposium-2023, Auckland. https://hdl.handle.net/10652/6102
Abstract
ccRCC
Patient
89Zirconium Girentuximab
Procedure
Pulmonary emboli
Pelvic embolic
Right teres muscle
Conclusion
References
Publisher
Australian and New Zealand Society of Nuclear Medicine
Permanent link
Link to ePress publication
DOI
Copyright holder
Authors
Copyright notice
All rights reserved